Ju Hyun Shim
Clinical trials sponsored by Ju Hyun Shim, explained in plain language.
-
Second-line hope: regorafenib tested after lenvatinib failure in liver cancer
Disease control Not yet recruitingThis study tests whether the drug regorafenib can help people with advanced liver cancer whose disease got worse after treatment with lenvatinib. About 24 adults will receive regorafenib and be monitored for how long their cancer stays under control and for side effects. The goal…
Phase: PHASE2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for liver cancer patients with liver damage: drug tested after immunotherapy fails
Disease control Not yet recruitingThis phase 2 trial tests the cancer pill regorafenib in 20 adults with advanced liver cancer and moderate liver dysfunction (Child-Pugh B) whose disease worsened after first-line immunotherapy. Participants take regorafenib daily for 3 weeks on, 1 week off, until the cancer progr…
Phase: PHASE2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC